Literature DB >> 7738143

The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo.

J Rose1, P Silvera, B Flanagan, P Kitchin, N Almond.   

Abstract

Polymerase chain reaction based assays, which amplify a region of the gag gene, have been developed for the direct detection of simian immunodeficiency virus (SIV) DNA sequences in the blood of experimentally infected cynomolgus macaques. In macaques infected with a characterised virus pool (11/88 pool SIVmac 32H), an assay employing a single round of amplification was found to be highly sensitive and specific. However, in animals infected with the SIV molecular clones J5 and C8 (Rud et al., J. Gen. Virol. 75, 529-543), it was necessary to use two rounds of amplification and nested primer pairs in order to achieve sensitivity > 90%. In order to differentiate macaques infected with either of the two genetically distinct SIV clones, J5 or C8, a third PCR based assay has been developed, which amplifies a 492 bp region of the nef gene. Sequence differences between the nef genes of the two molecular clones enabled the PCR product amplified from each virus to be distinguished by restriction analysis. These sensitive and specific assays complement virological detection of SIV and enable superinfection studies to be evaluated; a prerequisite for the testing of live attenuated immunodeficiency virus vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738143     DOI: 10.1016/0166-0934(94)00109-t

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence.

Authors:  A M Whatmore; N Cook; G A Hall; S Sharpe; E W Rud; M P Cranage
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

2.  Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates.

Authors:  T Lehner; Y Wang; M Cranage; L Tao; E Mitchell; C Bravery; C Doyle; K Pratt; G Hall; M Dennis; L Villinger; L Bergmeier
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

3.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Persistence and dissemination of simian retrovirus type 2 DNA in relation to viremia, seroresponse, and experimental transmissibility in Macaca fascicularis.

Authors:  Roseanne C Wilkinson; Claire K Murrell; Rebecca Guy; Gail Davis; Joanna M Hall; David C North; Nicola J Rose; Neil Almond
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.

Authors:  Mars Stone; Zhong-Min Ma; Meritxell Genescà; Linda Fritts; Shelley Blozois; Michael B McChesney; Christopher J Miller
Journal:  Virology       Date:  2009-08-03       Impact factor: 3.616

6.  Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodeficiency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques.

Authors:  Sean Clarke; Neil Berry; Claire Ham; Jack Alden; Neil Almond; Debbie Ferguson
Journal:  J Neurovirol       Date:  2012-03-09       Impact factor: 2.643

7.  Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.

Authors:  Mark Page; Ruby Quartey-Papafio; Mark Robinson; Mark Hassall; Martin Cranage; James Stott; Neil Almond
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.